LIMK inhibition blocks collective invasion of tumor cells: Researchers

NewsGuard 100/100 Score

Researchers have shown that LIM kinase (LIMK), an important regulator of actin cytoskeleton dynamics, plays a key role in cancer metastasis. The study appears online on September 27 in The Journal of Cell Biology www.jcb.org.

Cancer metastasis is a multi-stage process that starts with the invasion of tumor cells into their surrounding tissue. The ability of metastatic cells to invade requires reorganization of the actin-myosin cytoskeleton, which is controlled by a sophisticated network of signals sent between a number of cellular components.

LIMK has been shown previously to facilitate tumor invasion through its role in actin regulation. Researchers from the United Kingdom delved deeper into the role of LIMK in this process. The team showed that LIMK is specifically required for cells at the front of the invading tumor to clear a path that the remaining metastatic cells can follow. Working with breast cancer and squamous carcinoma cells, the team found that inhibiting LIMK function blocked the collective invasion of tumor cells, thus preventing these cells from metastasizing.

The authors propose that LIMK inhibitors might be effective in the treatment of cancers such as prostate cancer, where the presence of localized tumors might not be life threatening but mortality can result from metastasis.

Source: Rockefeller University Press

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Do neighborhood-level disparities in breast cancer–specific survival remain after accounting for individual, tumor, and treatment characteristics?